STOCK TITAN

NAVIDEA BIOPHARMS INC - NAVB STOCK NEWS

Welcome to our dedicated page for NAVIDEA BIOPHARMS news (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on NAVIDEA BIOPHARMS stock.

NAVIDEA BIOPHARMACEUTICALS, INC. (symbol: NAVB) is a prominent biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates through two main segments: Diagnostic Substances and Therapeutic Development Programs.

At the heart of Navidea's innovation is the Manocept Platform, designed to target the CD206 mannose receptor expressed on activated macrophages. This platform has broad applications across various diagnostic modalities, including Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), imaging, and topical gamma-scanning. Additionally, it facilitates intra-operative and/or optical-fluorescence detection, and the delivery of therapeutic compounds targeting macrophages and diseases involving immune and inflammation responses.

Navidea's product portfolio features NAV4694, a fluorine-18 labeled PET imaging agent used for imaging and evaluating patients exhibiting signs of Alzheimer's disease and mild cognitive impairment. This product underscores the company's commitment to addressing urgent medical needs through advanced diagnostics.

In terms of current projects and partnerships, Navidea continues to build strategic alliances to enhance its product offerings and broaden its market reach. Financially, the company remains focused on strategic investments and operational efficiencies to bolster its position in the biopharmaceutical sector.

Rhea-AI Summary

Navidea Biopharmaceuticals (NYSE American: NAVB) has announced the commencement of its rights offering subscription period. Rights holders must act quickly, as the deadline to exercise these rights is August 17, 2022, by 5:00 PM Eastern Time. Each subscription right allows the purchase of a unit for $1,000, including one share of Series I Convertible Preferred Stock and a warrant for 1,538 shares of common stock at an exercise price of $0.70. Maxim Group LLC will manage the offering, with further financial results expected on August 15, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
none
-
Rhea-AI Summary

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) announced the publication of a study showcasing Tc99m tilmanocept as an effective tracer for lymphatic mapping in melanoma and oral cancer. Conducted at the Crown Princess Mary Cancer Centre, the study involved 35 patients and reported a 100% sensitivity and intraoperative retrieval rate for sentinel lymph nodes. The findings support Tc99m tilmanocept's reliability as a radiotracer, enhancing the precision of cancer staging. The study's success highlights the potential for further expansion of Lymphoseek beyond North America.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
Rhea-AI Summary

Navidea Biopharmaceuticals (NYSE American: NAVB) announced the publication of a manuscript regarding its Tc99m tilmanocept imaging study. Conducted at Massachusetts General Hospital and Harvard Medical School, the research highlights increased macrophage-specific arterial inflammation in HIV patients on anti-retroviral therapy compared to matched controls. Results showed significant arterial inflammation in HIV patients, linking it to non-calcified plaque and specific immune activation pathways. This study suggests potential applications of Tc99m tilmanocept in monitoring cardiovascular risks in HIV treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
-
Rhea-AI Summary

Navidea Biopharmaceuticals (NYSE American: NAVB) announced its upcoming rights offering, allowing stockholders of record as of August 3, 2022 to participate. Each stockholder will receive a non-transferable subscription right to purchase one unit at a price of $1,000, consisting of newly created Series I Convertible Preferred Stock and warrants for common shares at an exercise price of $0.80. The subscription period runs from August 4 to August 17, 2022. Maxim Group LLC is the dealer-manager for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.48%
Tags
none
-
Rhea-AI Summary

Navidea Biopharmaceuticals (NYSE American: NAVB) announced on July 1, 2022, that its largest shareholder, John K. Scott, Jr., provided an additional $1.0 million funding via a secured bridge loan executed on April 10, 2022. Dr. Michael Rosol, Chief Medical Officer, expressed enthusiasm for the continued funding to support Phase 3 and R&D efforts. Navidea focuses on precision immunodiagnostic agents and immunotherapeutics, utilizing its Manocept™ platform to improve diagnostic accuracy and treatment targeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
none
Rhea-AI Summary

Navidea Biopharmaceuticals (NYSE American: NAVB) announced the acceptance of its abstract for presentation at the SNMMI Annual Meeting in Vancouver, Canada, from June 11-14. The abstract focuses on TAM-targeted imaging agents for tumor localization, developed in collaboration with the University of Alabama at Birmingham. The research aims to improve tumor imaging while reducing liver localization, showcasing promising results with new imaging agents labeled with gallium-68. This presentation highlights Navidea's commitment to advancing medical imaging and potential therapeutic strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags
none
-
Rhea-AI Summary

Navidea Biopharmaceuticals (AMEX: NAVB) announced the acceptance of its abstract for a poster presentation at the Tumor Myeloid-Directed Therapies Summit scheduled for June 14-16, 2022, in Boston, MA. The poster will highlight new bisphosphonate drug constructs developed using Navidea’s CD206-targeted drug delivery platform, Manocept. These constructs successfully shifted human macrophage phenotypes towards a proinflammatory state and significantly reduced SIRPα expression, which may enhance cancer immunotherapy applications. Chief Medical Officer Dr. Michael Rosol emphasized the potential of these constructs in treating severe illnesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary

Navidea Biopharmaceuticals, focused on precision immunodiagnostic agents, reported its Q1 2022 financial results. Total net revenues were $0, down from $124,000 in Q1 2021 due to previous debt recovery and license revenue. Net loss attributable to common stockholders was $3.0 million, or $0.10 per share, stable compared to $3.0 million, or $0.11 per share in 2021. Positive developments included ongoing Phase 3 and 2b trials for rheumatoid arthritis, regulatory approval for Lymphoaim in India, and new provisional patent applications, indicating progress in their pipeline. Investors can join the upcoming conference call for more insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.1%
Tags
Rhea-AI Summary

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is scheduled to hold a conference call on May 12, 2022, at 5:00 p.m. (EDT), to discuss its first quarter financial results and corporate developments. The call will feature Dr. Michael Rosol and Erika Eves, who will provide insights on financial performance and clinical progress. Investors can access the call via a web link and will have the opportunity to ask questions following the announcement. The company aims to enhance patient care through its innovative Manocept™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
conferences earnings

FAQ

What is the current stock price of NAVIDEA BIOPHARMS (NAVB)?

The current stock price of NAVIDEA BIOPHARMS (NAVB) is $0.001 as of November 21, 2024.

What is the market cap of NAVIDEA BIOPHARMS (NAVB)?

The market cap of NAVIDEA BIOPHARMS (NAVB) is approximately 100.1K.

What is Navidea Biopharmaceuticals, Inc. known for?

Navidea Biopharmaceuticals, Inc. is known for its development and commercialization of precision immunodiagnostic agents and immunotherapeutics.

What is the Manocept Platform?

The Manocept Platform is designed to target the CD206 mannose receptor on activated macrophages, applicable in various diagnostic and therapeutic applications.

What are the main segments of Navidea's operations?

Navidea operates through two segments: Diagnostic Substances and Therapeutic Development Programs.

What is NAV4694?

NAV4694 is a fluorine-18 labeled PET imaging agent used to aid in imaging and evaluating patients with Alzheimer's disease and mild cognitive impairment.

How does Navidea's technology benefit healthcare?

Navidea's technology aids in accurate diagnosis and targeted treatment, particularly in diseases involving immune and inflammation responses.

What diagnostic modalities does the Manocept Platform support?

The Manocept Platform supports SPECT, PET, imaging, topical gamma-scanning, intra-operative, and optical-fluorescence detection.

Does Navidea have any therapeutic products?

Yes, Navidea's platform also includes the delivery of therapeutic compounds targeting macrophages and related diseases.

What diseases does Navidea's technology target?

Navidea's technology targets immune and inflammation-involved diseases.

What is the focus of Navidea's recent projects?

Navidea focuses on strategic partnerships and technological advancements to enhance its diagnostic and therapeutic product offerings.

How does Navidea maintain its financial health?

Navidea remains focused on strategic investments and operational efficiencies to support its financial condition.

NAVIDEA BIOPHARMS INC

NYSE:NAVB

NAVB Rankings

NAVB Stock Data

100.08k
64.16M
35.89%
2.68%
Biotechnology
Healthcare
Link
United States of America
Dublin